Table 1.
Characteristics of the studies included in the meta-analysis
| Study | Region | Study design | n | FEV1% predicted (mean ± SD) | Trial drug (dose) | Trial time | Outcome |
|---|---|---|---|---|---|---|---|
| Block et al14 | USA | DB, COS, R, PC | 20 | 29–99 (53±21) | Flurazepam (30 mg) | 2 consecutive nights | TST, apnea |
| Timms et al15 | UK | DB, COS, R, PC | 10 | 17–76 (38±19) | Triazolam (0.125 mg, 0.25 mg) | 3 nights within a2-week period | TST, sleep duration, arousals/hour of sleep, percentage of time below 90% SaO2, time spent in stage 2 non-REM sleep, subjective sleep quality, mean SaO2, minimum SaO2, number of apneic and hypopneic events |
| Midgren et al16 | Sweden | DB, COS, R, PC | 14 | 31±11 | Nitrazepam (5 mg) flunitrazepam (1 mg) | 3 nights within a1-week period | Sleep latency, TST, SE, periods of wakefulness, apneas, maximum tcPCO2 increase |
| Steens et al17 | Canada | DB, COS, R, PC | 23 | 40–80 (61±12) | Triazolam (0.25 mg) | 4 consecutive nights | TST, sleep latency, arousals/total sleep time, SE, sleep quality (VAS) |
| Stege et al13 | the Netherlands | DB, COS, R, PC | 14 | 33.5±9.2 | Temazepam (10 mg) | 1 week | TST, SE, NWAK, sleep quality (VAS) (AHI, %TST) with SaO290% |
Abbreviations: DB, double-blind; COS, crossover study; R, randomized; PC, placebo-controlled; TST, total sleep time; SaO2, arterial oxygen saturation; REM, rapid eye movement; SE, sleep efficiency; tcPCO2, transcutaneous carbon dioxide pressure; VAS, visual analog scale; NWAK, number of awakenings; AHI, Apnea–Hypopnea Index.